Abstract:Background: Quinolones are widely prescribed for the treatment or prevention of infectious diseases in children. To gain further insight into quinolone-associated adverse event (AE) in children and better protect pediatric patients, continued surveillance of safety data is essential. The purpose of this study was to characterize the safety profiles of quinolone-associated AEs in children by mining the FDA adverse event reporting system (FAERS). Methods: FAERS reports from quarter 1 of 2004 to quarter 1 of 2022 were included in the study. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify adverse events. Reporting odds ratios (ROR) corresponding 95% confidence intervals (CIs) and information component (IC) along with 95% CIs were calculated to detect drug–AE pairs with higher-than-expected reporting rates within the FAERS from System Organ Classes (SOCs) to Preferred Terms (PTs). Reports were considered as signals if the 95% confidence interval did not contain the null value. Results: After inclusion criteria were applied, a total of 4,704 reports associated with quinolones were considered. Most FAERS reports associated with ciprofloxacin ( N = 2,706) followed by levofloxacin ( N = 1,191), moxifloxacin ( N = 375), oflaxacin ( N = 245) and ozenoxacin ( N = 187). The most common age group was 12–18 years. The median weight was 39.0 kilogram. The adverse effects of quinolones emerging for SOCs primarily included Infections and infestations, gastrointestinal symptoms, blood and lymphatic system disorders, cardiac disorders, nervous system disorders, musculoskeletal and connective tissue disorders and psychiatric disorders. The most frequently AE signals at the PT level were pyrexia ( N = 236), febrile neutropenia ( N = 120), off label use ( N = 48), drug resistance ( N = 18) and cardiac arrest ( N = 22) following the use of ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, and ozenoxacin, respectively. Serious oznoxacin-associated AE signals were found and have not been documented in the package insert. They included cardiac arrest ( N = 22; ROR = 19.83; IC = 3.68), overdose ( N = 21; ROR = 4.98; IC = 2.07), seizure ( N = 16; ROR = 6.01; IC = 2.29), small for dates baby ( N = 9; ROR = 14.7; IC = 3.05), completed suicide ( N = 15, ROR = 18.87; IC = 3.51), asthma ( N = 9; ROR = 6.69; IC = 2.24;) and hypotension ( N = 9; ROR = 3.83; IC = 1.68). Conclusion: This study provided additional evidence with respect to quinolones-related AEs for children. Generally, the findings of this study are compatible with AEs recorded in package inserts. The unexpected signals of ozenoxacin justify active vigilance by clinicians and timely monitoring by pharmacovigilance experts.

Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report

Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database

Safety profiles of doxycycline, minocycline, and tigecycline in pediatric patients: a real-world pharmacovigilance analysis based on the FAERS database

Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database

A multi-center survey on the application of antibacterial agents in Chinese children in 2019

Safety analysis of quinolones use in minors-based on the FAERS database

A Computational Method to Quantitatively Measure Pediatric Drug Safety Using Electronic Medical Records

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)

Mohnarin Report of 2011: Surveillance of Bacterial Resistance in Patients Aged Between 0 and 14

Safety of Quinolones in Children: A Systematic Review and Meta-Analysis

Selection and Application Opportunity of Antibiotics in Children with Respiratory Tract Infections

Long-Term Safety Profiles of Macrolides and Tetracyclines: A Systematic Review and Meta-Analysis

Safety profiles and adverse reactions of azithromycin in the treatment of pediatric respiratory diseases: A systematic review and meta-analysis

Retrospective analysis of tigecycline shows that it may be an option for children with severe infections

Risk of Dental Discoloration and Enamel Dysplasia in Children Exposed to Tetracycline and Its Derivatives

How safe is doxycycline for young children or for pregnant or breastfeeding women?

Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database

Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS

Retrospective analysis of cefpodoxime proxetil dispersible tablets in the treatment of respiratory tract infection in children and study of the antibacterial effect of cefpodoxime proxetil nanoemulsion

Pharmacokinetic and Pharmacodynamic Considerations of Novel Antibiotic Agents for Pediatric Infections: A Narrative Review

Treatment of Macrolide-resistant Mycoplasma pneumoniae Pneumonia in Children: A Meta-analysis of Macrolides Versus Tetracyclines.